Abstract:PurposeTo evaluate quality of life (QoL) with a new questionnaire after canaloplasty (CP) and trabeculectomy (TE).Patients and methodsWe assessed outcomes of surgery, rate of revision surgeries, patients’ mood, and influence of postoperative care on QoL, surgery interference with daily activities, and postsurgical complaints. Patients completed the QoL questionnaire 24 months after surgery.ResultsPatients who underwent CP (n=175) were compared to TE patients (n=152). In the CP group, 57% of patients expressed … Show more
“…This entailed the lack of preset: (a) randomization procedure, (b) cut-off values for target IOP, and (c) intermediate follow-up time points. The administration of a survey to evaluate quality of life, as proposed by Klink and coauthors in a quite similar setting, could represent a further improvement to the present findings [ 18 ].…”
The results of canaloplasty (CP) and Hydrus Microstent (HM) implantation were retrospectively compared at 24 months' follow-up in a cohort of subjects referred to our Institution for uncontrolled IOP in primary or secondary (e.g., pseudoexfoliative and pigmentary) open-angle glaucoma. The outcome was labelled as “complete” success, “qualified” success, or “failure” if, two years after surgery, the eyes operated on needed “no” hypotensive medications, “some” hypotensive medications, or further glaucoma surgery to attain the target IOP, respectively. Both CP and HM implant allowed significant IOP reductions, with comparable rate of clinical success and safety profile. A slightly (albeit not significant) better trend for a “complete” clinical success was observed in the CP group.
“…This entailed the lack of preset: (a) randomization procedure, (b) cut-off values for target IOP, and (c) intermediate follow-up time points. The administration of a survey to evaluate quality of life, as proposed by Klink and coauthors in a quite similar setting, could represent a further improvement to the present findings [ 18 ].…”
The results of canaloplasty (CP) and Hydrus Microstent (HM) implantation were retrospectively compared at 24 months' follow-up in a cohort of subjects referred to our Institution for uncontrolled IOP in primary or secondary (e.g., pseudoexfoliative and pigmentary) open-angle glaucoma. The outcome was labelled as “complete” success, “qualified” success, or “failure” if, two years after surgery, the eyes operated on needed “no” hypotensive medications, “some” hypotensive medications, or further glaucoma surgery to attain the target IOP, respectively. Both CP and HM implant allowed significant IOP reductions, with comparable rate of clinical success and safety profile. A slightly (albeit not significant) better trend for a “complete” clinical success was observed in the CP group.
“…In 2014, Klink and coworkers [ 27 ] assessed quality of life and patient satisfaction after canaloplasty and trabeculectomy. Patients reported a better quality of life after canaloplasty, particularly with regard to positive postoperative mood, satisfaction with outcome, and lower rates of visual and nonvisual symptoms.…”
Canaloplasty is a nonpenetrating blebless surgical technique for open-angle glaucoma, in which a flexible microcatheter is inserted within Schlemm's canal for the entire 360 degrees. When the microcatheter exits the opposite end, a 10-0 prolene suture is tied and it is then withdrawn, by pulling microcatheter back through the canal in the opposite direction. Ligation of prolene suture provides tension on the canal and facilitates aqueous outflow. The main advantage of canaloplasty is that this technique avoids the major complications of fistulating surgery related to blebs and hypotony. Currently, canaloplasty is performed in glaucoma patients with early to moderate disease and combination with cataract surgery is a suitable option in patients with clinically significant lens opacities.
“…Over a decade after the first Canaloplasty procedure was performed, evidence pertaining to the long-term efficacy and safety of this noninvasive, restorative glaucoma surgery continues to accumulate. Today, more than 50 peer-reviewed clinical studies attest to the fact that Canaloplasty is as effective as trabeculectomy in lowering intraocular pressure (IOP) and reducing dependence on medications [ 1 – 6 ].…”
Canaloplasty is a highly effective, minimally invasive, surgical technique indicated for the treatment of open-angle glaucoma that works by restoring the function of the eye's natural outflow system. The procedure's excellent safety profile and long-term efficacy make it a viable option for the majority of glaucoma patient types. It can be used in conjunction with existing drug based glaucoma treatments, after laser or other types of incisional surgery, and does not preclude or affect the outcome of future surgery. Numerous scientific studies have shown Canaloplasty to be safe and effective in lowering IOP whilst reducing medication dependence. A recent refinement of Canaloplasty, known as ab-interno Canaloplasty (ABiC), maintains the IOP-lowering and safety benefits of traditional (ab-externo) Canaloplasty using a more efficient, simplified surgical approach. This paper presents a review of Canaloplasty indications, clinical data, and complications, as well as comparisons with traditional incisional glaucoma techniques. It also addresses the early clinical evidence for ABiC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.